- Article
Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
- Kristine A. Frerichs,
- Christie P. M. Verkleij,
- Meletios A. Dimopoulos,
- Jhon A. Marin Soto,
- Sonja Zweegman,
- Mary H. Young,
- Kathryn J. Newhall,
- Tuna Mutis and
- Niels W. C. J. van de Donk
Daratumumab is active both as a single agent and in combination with other agents in multiple myeloma (MM) patients. However, the majority of patients will develop daratumumab-refractory disease, which carries a poor prognosis. Since daratumumab also...